and different immune cell types, and even subdivisions within distinct cell populations utilize different metabolic pathways to optimize function
The evidence indicates that semaglutide leads to both scale wins and targeted internal fat loss, and these two outcomes are related but distinct
The authors demonstrate that GLP-1R agonist treatment induces expression of tyrosine kinase IGF1R/ErbB (EGFR) pathways, however, agonist treatment can still increase intestinal growth in the absence of intestinal epithelial IGF1 receptor as well as EGF receptor signaling (Koehler et al., 2015)
Key Takeaway: The primary risk for those with diverticulitis taking GLP-1s is not the medication itself, but the side effect of constipation, which can increase colonic pressure and trigger a flare
While these findings are intriguing, the leap from controlled laboratory settings to the complex biological environment of the human body is significant and uncertain